GLPG vs. AMRX, EVO, GPCR, AGIO, RNA, NAMS, RCKT, SNDX, CPRX, and SDGR
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Avidity Biosciences (RNA), NewAmsterdam Pharma (NAMS), Rocket Pharmaceuticals (RCKT), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
Galapagos has higher earnings, but lower revenue than Amneal Pharmaceuticals.
32.5% of Galapagos shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Galapagos currently has a consensus target price of $34.50, indicating a potential upside of 20.84%. Amneal Pharmaceuticals has a consensus target price of $8.25, indicating a potential upside of 23.87%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Galapagos.
Galapagos has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
In the previous week, Amneal Pharmaceuticals had 11 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Amneal Pharmaceuticals and 2 mentions for Galapagos. Galapagos' average media sentiment score of 1.12 beat Amneal Pharmaceuticals' score of 0.86 indicating that Galapagos is being referred to more favorably in the media.
Galapagos received 457 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Amneal Pharmaceuticals has a net margin of -6.76% compared to Galapagos' net margin of -26.25%. Amneal Pharmaceuticals' return on equity of 234.06% beat Galapagos' return on equity.
Summary
Amneal Pharmaceuticals beats Galapagos on 11 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
